MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE
The present invention relates to compositions, methods and kits using cell phenotype altering polynucleotides, cell phenotype altering primary transcripts and cell phenotype altering mmRNA molecules.
1 . A method for altering a cell phenotype comprising contacting the cell with a composition comprising at least a first cell phenotype altering polynucleotide, wherein said first cell phenotype altering polynucleotide comprises:
(a) a first region of linked nucleosides, said first region encoding a Granulocyte-colony stimulating factor (G-CSF) polypeptide or a functional variant or fragment thereof;
(b) a first flanking region located at the 5′ terminus of said first region comprising:
(i) a sequence of linked nucleosides selected from the group consisting of the native 5′ untranslated region (UTR) of any of SEQ ID NOs: 269-394, SEQ ID NO: 1 and functional variants thereof; and
(c) a second flanking region located at the 3′ terminus of said first region comprising:
(i′) a sequence of linked nucleosides selected from the group consisting of the native 3′ UTR of any of SEQ ID NOs: 269-394,
SEQ ID NOs 2-7 and functional variants thereof; and
(ii′) a 3′ tailing sequence of linked nucleosides;
wherein the first region of linked nucleosides are fully modified with N1-methylpseudouridine at each uridine.
2 . The method of claim 1 wherein the first cell phenotype altering polynucleotide comprises a poly-A tail.
3 . The method of claim 2 , wherein the first cell phenotype altering polynucleotide comprises at least one 5′ cap structure.
4 . The method of claim 1 , wherein the first region of the first cell phenotype altering polynucleotide comprises a sequence set forth in SEQ ID NOs: 405-407.
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . The method of claim 1 , wherein the cell is a human cell.
10 . The method of claim 1 , wherein the cell is contacted at least twice.
11 . The method of claim 1 , wherein the cell is contacted a plurality of times.
12 . The method of claim 1 , wherein the composition further comprises a second cell phenotype altering polynucleotide, wherein said second cell phenotype altering polynucleotide comprises:
(a) a first region of linked nucleosides, said first region encoding a cell phenotype altering polypeptide selected from the group consisting of SEQ ID NOs: 269-394;
(b) a first flanking region located at the 5′ terminus of said first region comprising;
(i) a sequence of linked nucleosides selected from the group consisting of the native 5′ untranslated region (UTR) of any of
SEQ ID NOs: 269-394, SEQ ID NO: 1 and functional variants thereof; and
(c) a second flanking region located at the 3′ terminus of said first region comprising;
(i′) a sequence of linked nucleosides selected from the group consisting of the native 3′ UTR of any of SEQ ID NOs: 269-394,
SEQ ID NOs 2-7 and functional variants thereof; and
(ii′) a 3′ tailing sequence of linked nucleosides;
wherein the first region of linked nucleosides comprises at least a first modified nucleoside.
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . A composition comprising at least a first cell phenotype altering polynucleotide, wherein said first cell phenotype altering polynucleotide comprises:
(a) a first region of linked nucleosides, said first region encoding a Granulocyte-colony stimulating factor (G-CSF) polypeptide or a functional variant or fragment thereof;
(b) a first flanking region located at the 5′ terminus of said first region comprising:
(i) a sequence of linked nucleosides selected from the group consisting of the native 5′ untranslated region (UTR) of any of SEQ ID NOs: 269-394, SEQ ID NO: 1 and functional variants thereof; and
(c) a second flanking region located at the 3′ terminus of said first region comprising:
(i′) a sequence of linked nucleosides selected from the group consisting of the native 3′ UTR of any of SEQ ID NOs: 269-394, SEQ ID NOs 2-7 and functional variants thereof; and
(ii′) a 3′ tailing sequence of linked nucleosides;
wherein the first region of linked nucleosides are fully modified with N1-methylpseudouridine at each uridine.
18 . The composition of claim 17 , further comprising a second cell phenotype altering polynucleotide, wherein said second cell phenotype altering polynucleotide comprises:
(a) a first region of linked nucleosides, said first region encoding a cell phenotype altering polypeptide selected from the group consisting of SEQ ID NOs: 269-394;
(b) a first flanking region located at the 5′ terminus of said first region comprising:
(i) a sequence of linked nucleosides selected from the group consisting of the native 5′ untranslated region (UTR) of any of SEQ ID NOs: 269-394, SEQ ID NO: 1 and functional variants thereof; and
(c) a second flanking region located at the 3′ terminus of said first region comprising:
(i′) a sequence of linked nucleosides selected from the group consisting of the native 3′ UTR of any of SEQ ID NOs: 269-394, SEQ ID NOs 2-7 and functional variants thereof; and
(ii′) a 3′ tailing sequence of linked nucleosides;
wherein the first region of linked nucleosides comprises at least a first modified nucleoside.
19 . A kit comprising the composition of claim 17 .
20 . (canceled)